- Home
- UTMD vs EYPT Comparison
UTMD vs EYPT Comparison
Compare UTMD & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UTMD | EYPT |
|---|---|---|
| Founded | 1978 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 235.3M | 273.3M |
| IPO Year | 1994 | 2005 |
Fundamental Metrics
Financial Performance| Metric | UTMD | EYPT |
|---|---|---|
| Price | $74.81 | $3.35 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $25.91 |
| AVG Volume (30 Days) | 28.0K | ★ 3.2M |
| Earning Date | 10-22-2026 | 11-04-2026 |
| Dividend Yield | ★ 1.66% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.66 | N/A |
| Revenue | ★ $38,520,000.00 | $7,539,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $967.16 |
| P/E Ratio | $45.01 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $53.66 | $3.05 |
| 52 Week High | $76.89 | $19.11 |
Technical Indicators
Market Signals| Indicator | UTMD | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 54.92 | 33.95 |
| Support Level | $73.22 | $3.05 |
| Resistance Level | $75.38 | $14.72 |
| Average True Range (ATR) | 0.83 | 0.23 |
| MACD | -0.12 | 0.19 |
| Stochastic Oscillator | 33.78 | 26.51 |
Price Performance
Historical ComparisonAbout UTMD Utah Medical Products Inc.
Utah Medical Products Inc is involved in the business of developing, manufacturing, and distributing medical devices that are mainly proprietary, disposable, and for hospital use. The firm produces its products for Blood pressure monitoring, Blood collection, Electrosurgery, Gynecology, Neonatal critical care, perinatology, and Urology. The company's product portfolio includes Electrosurgical pens, Tenacula, Endoscopic bulb irrigators, and Blood bag spikes. Its products are used mainly in critical care areas, labor and delivery departments of hospitals, and outpatient clinics and physicians' offices.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.